announces investment report featuring GenVec announces an investment report featuring GenVec Inc. (Nasdaq:GNVC). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at:

Get our alerts BEFORE the rest of the market. Follow us on Twitter:

GenVec Inc. (GNVC) is a clinical stage biopharmaceutical company developing gene-based therapeutic drugs and vaccines. Its lead product candidate, TNFerade biologic (TNFerade), is being developed for use in the treatment of cancer. Using GNVC's core adenovector technology, TNFerade stimulates the production of tumor necrosis factor alpha (TNFa), a known anti-tumor protein, in cells of the tumor. In addition to its therapeutic product development programs, GNVC is working with collaborators to develop new applications for its technology through its vaccine development programs. The Company is developing a vaccine in animal health against foot-and-mouth disease and preventative vaccines for malaria, human immunodeficiency virus (HIV), respiratory syncytial virus and Herpes Simplex Virus Type 2 (HSV-2). 

Message Board Search for GNVC:

In the report, the analyst notes:

"GNVC last week announced financial results for the fourth quarter and year ended December 31, 2009. For the fourth quarter ended December 31, 2009, GNVC reported a net loss of $4.3 million, or $0.04 per share, compared with a net loss of $6.4 million, or $0.07 per share, for the comparable prior year period. The Company reported revenues of $3.4 million in the fourth quarter of 2009 compared to $3.3 million for the same period in 2008. 

"GNVC recently announced the publication of new preclinical research revealing mechanisms by which TNFerade™ suppresses cancer metastases through activation of the immune system."



The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers identify two risk factors that indicate higher risk of aggressive prostate cancer